Mirion Q2 Guidance Reaffirmed but RPO Slips, No New Large Nuclear Wins

What happened

Mirion Technologies reported Q2 2026 results on July 29, holding its earnings call and reaffirming full-year adjusted EBITDA of $285–$300 million and adjusted free cash flow of $155–$175 million. Remaining performance obligations (RPO) slipped to approximately $1.08 billion from $1.104 billion at year-end 2025, reflecting normal conversion but no acceleration from new large orders. Organic revenue growth guidance remained at 5–7%, falling short of the 8–9% some investors had hoped for from the nuclear up-cycle. No incremental large-opportunity pipeline wins were disclosed beyond prior announcements, underscoring that the nuclear demand narrative has yet to translate into a clear order inflection. The second half of 2026 now becomes the critical window for new large-order catalysts to justify Mirion’s premium valuation.

Implication

Mirion’s valuation embeds a nuclear renaissance that Q2 results did not reinforce. While contract visibility still supports the base case, the next six months must deliver sizable new orders to sustain an EV/EBITDA above 28x. Without them, the stock risks drifting toward the $19 entry level as interest costs and dilution overhangs weigh on sentiment. Investors should scrutinize the 10-Q for any downward revision to the 49% RPO conversion expectation—an early warning of execution delays.

Thesis delta

The Q2 update modestly increases the probability that Mirion’s nuclear order growth is slower than priced in. Failure to raise organic guidance or announce fresh large pipeline awards shifts conviction slightly toward the bear scenario. The base case holds, but the investment hinges more on H2 2026 catalysts to restore momentum.